Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug monitored for rare skin cancer patients

NCT ID NCT07132567

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 30 times

Summary

This study watches how safe and effective the drug mogamulizumab is for adults with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. About 15 people will be followed during their normal treatment to track side effects and how well the drug controls the disease. The goal is to see how the drug works in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chung-Ang University Hospital

    TERMINATED

    Seoul, South Korea

  • Ewha Womans University Mokdong Hospital

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Kosin University Gospel Hospital

    RECRUITING

    Busan, Busan Metropolitan City, 49267, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.